Benjamin Rolles
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of luspatercept in TD LR-MDS. Six databases were searched through March 2025 to find relevant material. Studies were screened and extracted by 2 independent authors. A total of 20 studies encompassing 3455 patients were included in the analysis. The pooled 8-week transfusion independence (TI) rate was 51.2% (95% confidence interval [CI], 39.9-60.4; I2 = 94.9%), with higher rates observed among ring sideroblast–positive (RS+) patients (57.8%; 95% CI, 47.4-67.7; I2 = 86%) and those with low transfusion burden (LTB; 72.9%; 95% CI, 60.4-82.6; I2 = 0%). The 12-week and 24-week TI rates were 57.0% (95% CI, 48.1-65.5; I2 = 90%) and 35.8% (95% CI, 28.7-43.6; I2 = 82.1%), respectively. Hematologic improvement–erythroid was achieved in 51.3% of patients (95% CI, 41.3%–61.2%; I2 = 93%). The most frequent adverse events were peripheral edema (17.8%; 95% CI, 11.4-26.8), diarrhea (15.6%; 95% CI, 8.2-27.7), and fatigue (11.4%; 95% CI, 5.4-22.6). Serious adverse events occurred in 28.0% of patients (95% CI, 12.8-50.7; I2 = 97.2%). Luspatercept is an effective and well-tolerated treatment for anemia in TD LR-MDS, especially in patients with RS+ and LTB. Its favorable safety profile and high TI rates, particularly in erythropoiesis-stimulating agent–naïve populations, support its use in the frontline setting.
Year:
2025
Acute myeloid leukaemia (AML) is a haematopoietic malignancy that continues to demonstrate lapses in current treatment modalities as evidenced by therapy refractory disease, disease relapse and high rates of lethality. The influence of nutritional factors, including trace elements, on disease development and progression is not yet well understood. We utilized AML cell lines and patient samples to further investigate zinc homeostasis and the dependency of leukaemic cells on zinc. Compared to control individuals, we found significantly increased zinc levels in malignant blasts with concomitant serum hypozincaemia. Increased cellular zinc levels were accompanied by the upregulation of zinc influx transporters such as ZIP6 , ZIP9 and ZIP10 . Subsequent in vitro experiments showed the importance of zinc for myeloid cell proliferation, survival and block of differentiation. We validated our results with data from the Leukemia Mile ( n = 542) and the BeatAML2.0 study ( n = 805). Importantly, we identified ZIP10 (as one of the highly upregulated zinc transporters in malignant blasts) which, when targeted, resulted in impaired zinc uptake and decreased malignant cell growth. These findings suggest that therapeutic approaches that target the zinc influx transporter ZIP10 may offer novel means of treatment for patients suffering from AML.
Year:
2025
e18574 Background: Myelodysplastic syndromes (MDS) are bone marrow disorders often leading to anemia and transfusion dependence (TD). Luspatercept (Lusp) has shown promise in reducing transfusion needs in lower-risk (LR)-MDS patients (pts). This study evaluates the efficacy and safety of Lusp for transfusion-dependent MDS pts. Methods: A systematic review and meta-analysis was conducted (CRD42024574093). Studies published prior to 8/2024 were identified through six databases. Two independent reviewers assessed studies against inclusion and exclusion criteria. The risk of bias was assessed using the Cochran and Downs & Black quality assessment checklists. A random-effects model was used to pool outcomes, and heterogeneity was measured using the I² statistic. Finally, dedicated subgroup analyses were conducted. Results: A total of 693 studies were identified, from which 13 were included, that have 3 clinical trials and 10 cohort studies. These studies collectively included 2,614 pts, from those, 2331 received Lusp, and 1478 were TD before starting treatment. The quality assessment revealed that 6 studies were rated excellent, 3 good, 2 fair, and 1 poor. The results demonstrated the efficacy of Lusp in achieving TI at both 8 and 12 weeks (52.2% and 45.6%, respectively), with a well-tolerated safety profile (Table). The Quality of Adjusted Life Year during Lusp treatment for ESA-refractory pts was 0.721. No statistically significant publication bias was observed regarding any of the study's primary endpoints. Conclusions: The study findings support the use of Lusp, particularly in frontline settings for LR-MDS pts with Ring Sideroblasts. Lusp demonstrated responses in ESA-resistant populations. Baseline Characteristics n K Age (mean) 2614 12 73.5 years Sex (male) 2614 12 57.7% IPSS-R (Very low/Low) 565 5 75.9% SF3B1 617 5 53.7% Outcome n K Pooled Percentage (95% CI; I²) TI at 8 weeks L1&RS+ Refractory to ESA/RS+ Refractory to ESA/RS- Refractory to Lusp/ESA or HTB 1445450443365184 104333 52.2 (39.1 – 65.0; 95%)80.7 (72.7 – 86.9; 65%)42.8 (25.9 – 61.6; 95%)45.2 (33.0 – 57.9; 87%)29.9 (19.8 – 42.3; 74%) TI at 12 weeks L1&RS+ Refractory to ESA/RS+ Refractory to ESA/RS- 809189261321 5222 45.6 (31.7 – 60.2; 95%)67.7 (60.7 – 74.0; 0%)45.9 (32.8 – 59.6; 84%)37.2 (26.1 – 49.8; 90%) Acute Myeloid Leukemia transformation 536 3 2.6 (1.5 – 4.3; 0%) Serious Adverse Events 1058 4 28.1 (13.6 – 49.2; 98%) Peripheral edema 335 2 18.8 (12.8 – 26.6; 81%) Fatigue 443 3 16.8 (8.6 – 30.2; 90%) Back pain 335 2 16.1 (10.8 – 23.2; 79%) Diarrhea 443 3 14.5 (6.0 – 31.0; 90%) Dizziness 418 3 12.4 (6.1 – 23.5; 85%) n: Number of pts; K: number of studies; TI: Transfusion Independence; CI: Confidence Interval; L1: Frontline Setting; RS: Ring Sideroblasts; ESA: Erythropoiesis-Stimulating Agents; Lusp: Luspatercept; HTB: High Transfusion Burden; Refractory: Not responding to or resistant to treatment; I²: Measure of heterogeneity.
Year:
2025
Year:
2024
Introduction: Although the inferred “fitness” of clonal hematopoesis (CH) driver mutations differs depending on the gene mutation, the impact of environmental factors that may promote or impair CH expansion remain largely unknown. We hypothesized that obesity influences the clonal expansion rate of common CH driver mutations. Methods: To test this hypothesis, we first interrogated data from the UKBiobank (UKBB) (n=425,573 exomes) to evaluate the relationship between body mass index (BMI) (kg/m2) and four common CH mutations, namely DNMT3A, TET2, ASXL1, and JAK2. For functional studies we focused on JAK2V617F, using a novel Fgd5-CreER-Jak2V617F mouse model we generated. In this model, Jak2V617F expression is induced in a small percentage of long-term (LT)-HSC which are tracked sequentially in primary mice in an unirradiated bone marrow niche. To quantify Jak2V617F expression in the model, we developed a digital droplet PCR assay. We also generated a chimeric bone marrow transplant Jak2V617F model and performed bulk RNA-sequencing (RNAseq) on purified lineagelow Sca-1+ c-kithigh (LSK) cells expressing Jak2V617F or wild-type Jak2, isolated from the same mouse. Finally, we performed single-cell RNAseq on Jak2V617F-expressing c-kithigh cells purified from chimeric transplant mice. Mice fed an obesity diet received 60 kcal% fat while mice fed a control diet received 10 kcal% fat. Results: In UKBB analyses, we identified genotype-specific patterns of association between BMI and the presence of CH mutations. JAK2 (OR 0.51; 95% CI 0.27-0.96; p=0.036) and DNMT3A mutations (OR 0.92; 95% CI 0.87-0.97; p=0.0028) were negatively associated with a BMI >30 relative to BMI <25, whereas mutations in ASXL1(OR 1.40; 95% CI 1.23-1.60; p=8.8x10-7) and TET2 (OR 1.16; 95% CI 1.04-1.31; p=0.0095) were positively associated with BMI >30. To further explore the negative association between JAK2V617F and obesity, we generated a cohort of Fgd5-CreER-Jak2V617F mice and fed half the mice an obesity diet and the other half a control diet. After 24 weeks, Jak2-mutant mice fed the control diet developed a significantly higher hematocrit (HCT) as compared to Jak2-mutant mice fed the obesity diet (p=0.0043). The HCT remained significantly higher in control mice as compared to obese mice over a 46-week period (p<0.0001). Strikingly at 46 weeks, 5/7 mice (71%) fed the control diet showed signs of MPN as compared with 0/6 mice (0%) fed the obesity diet. Furthermore, overall survival was significantly improved in Jak2-mutant obese mice as compared to Jak2-mutant mice fed a control diet (p=0.03). Subsequently, after the death of most control mice, one Jak2-mutant obese mouse developed an elevated HCT, indicating that obesity prolonged the latency to MPN development in Jak2V617F mice. In the chimeric transplant model, gene set enrichment analysis (GSEA) showed significantly increased interferon alpha (NES=2.55, FDR≈0), interferon gamma (NES=2.26, FDR≈0), and interleukin-6 (NES=2.15, FDR=5.46x10-05) signaling in Jak2-mutant LSK cells isolated from obese animals as compared to wild-type LSK cells, a finding not observed in control mice. Single-cell RNAseq experiments further validated these findings, where we identified interferon induced transmembrane protein 1 (IFITM1) as one of the most differentially upregulated genes in Jak2-mutant LT-HSCs from obese mice (adjusted p-value=1.08x10-54) as compared to wild-type LT-HSCs, and unlike Jak2-mutant LT-HSCs from control mice. Conclusions: To our knowledge, our study is the largest to date to evaluate the relationship between obesity and CH and the first to investigate the negative association between JAK2V617F CH and obesity, using functional studies. We developed a novel Fgd5-CreER-Jak2V617F mouse model, which allowed us to study the transition from CH to overt MPN in an unperturbed, non-irradiated bone marrow niche. Transcriptomic profiling points to activation of the interferon signaling pathway in Jak2-mutan
Year:
2024
Background: Telomeres are the end-capping structures of all eukaryotic chromosomes thereby protecting the genome from damage and degradation. During the aging process, telomeres shorten continuously with each cell division until critically short telomeres prevent further proliferation whereby cells undergo terminal differentiation, senescence, or apoptosis. Premature aging due to critically short telomere length (TL) can also result from pathogenic germline variants in the telomerase complex or related genes that typically counteract replicative telomere shortening in germline and certain somatic cell populations, e.g., hematopoetic stem cells. Inherited diseases that result in altered telomere maintenance are summarized under the term telomere biology disorder (TBD). Summary: Since TL both reflects but more importantly restricts the replicative capacity of various human tissues, a sufficient telomere reserve is particularly important in cells with high proliferative activity (e.g., hematopoiesis, immune cells, intestinal cells, liver, lung, and skin). Consequently, altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis. Key Messages: The recognition of a potential congenital origin in approximately 10% of adult patients with clinical BMF is of utmost importance for the proper diagnosis, appropriate patient and family counseling, to prevent the use of inefficient treatment and to avoid therapy-related toxicities including appropriate donor selection when patients have to undergo stem cell transplantation from related donors. This review summarizes the current state of knowledge about TBDs with particular focus on the clinical manifestation patterns in children (termed early onset TBD) compared to adults (late-onset TBD) including typical treatment- and disease course-related complications as well as their prognosis and adequate therapy. Thereby, it aims to raise awareness for a disease group that is currently still highly underdiagnosed particularly when it first manifests itself in adulthood.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (12)
Shai Shimony
Dana-Farber Cancer Institute
Vikas Gupta
-
Marlise Luskin
Dana-Farber Cancer Institute
Geoffrey Uy
Professor of Medicine
Washington University School of Medicine
Luca Lanino
Yale University
Jana Jakobs
RWTH Aachen University
Lothar Rink
Director and Full Professor
Medizinische Fakultät der RWTH Aachen
Jessica Stempel
Assistant Professor
Knight Cancer Institute, Oregon Health and Science University
Lachelle Dawn Weeks
Dana-Farber Cancer Institute
Daniel DeAngelo
Chief of the Division of Leukemia
Dana-Farber Cancer Institute
Nikolai A. Podoltsev
Yale University
Inga Wessels
University Hospital RWTH Aachen
Make your next move.
Prepare your application
Review drafts before you send them.